R
Rajat Nandi
Researcher at Assam University
Publications - 5
Citations - 142
Rajat Nandi is an academic researcher from Assam University. The author has contributed to research in topics: Docking (molecular) & Virtual screening. The author has an hindex of 3, co-authored 5 publications receiving 71 citations.
Papers
More filters
Journal ArticleDOI
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
TL;DR: Rutin, a bioflavonoid and the antibiotic, doxycycline, is identified as the most potent inhibitor of SARS-CoV-2 envelope protein, which is a essential role in the assembly and formation of the infectious virion particles.
Journal ArticleDOI
Evaluation of Flavonoids as 2019-nCoV Cell Entry Inhibitor Through Molecular Docking and Pharmacological Analysis
TL;DR: In this article, the authors aimed at the receipt binding domain of S protein and ACE-2 receptor as promising drug targets against SARS-CoV-2 Flavonoids with anti-viral properties were taken as ligand for molecular docking Selected flavonoids showed extremely good pharmacokinetics properties with good absorption, solubility, metabolism, excretion, distribution, bioavailability and minimal toxicity.
Journal ArticleDOI
Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach
TL;DR: In this paper, a unique collection of 248 plant compounds were selected based on their antiviral activity published in previous literature and were subjected to molecular docking analysis against the catalytic sub-unit of RdRp.
Journal ArticleDOI
Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of Leishmania donovani nuclear DNA primase using ligand based virtual screening, docking and molecular dynamics approaches.
TL;DR: This study aimed Ld-PriS for the first time as a prospective target for the application of drug against Leishmania parasite and showed very poor binding affinity toward the catalytic subunit of human primase indicating their safety toward the host normal replication mechanism.
Journal ArticleDOI
Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase.
TL;DR: Free energy calculation by MM-PBSA and MM-GBSA analysis suggests that pritelivir may work as viable therapeutics for efficient drug advancement against Sars-CoV-2 Nsp13 helicase, potentially arresting the SARS-Cov-2 replication.